MDx Business Helps Meridian Q2 Revenues Spike 32 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Meridian Bioscience today reported a 32 percent jump in second quarter revenues, aided by "strong" results from its molecular diagnostic test for C. difficile and its recently acquired Bioline business.

For the three months ended March 31, Meridian posted $41.1 million in revenues, up from $31.1 million a year ago, but slightly short of consensus Wall Street expectations of $41.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.